Intravascular lymphomas are rare lymphoproliferative disorders characterized by the selective growth of malignant lymphoid cells within the lumina of small vessels. On histological and immunohistochemical examination, around 90% of reported cases meet the criteria of large B-cell lymphoma 1 and are categorized into a distinct entity in the WHO classification under the designation intravascular large B-cell lymphoma (IVLBCL). 2 Although IVLBCL can involve extranodal sites in virtually any organ, skin and central nervous system are predilection sites in Western countries, whereas Asian patients more often present with involvement of bone marrow, liver and spleen. 1, 3, 4 The presence of isolated cutaneous lesions is associated with a better outcome, 5 whereas central nervous system IVLBCL has particularly poor survival. 1 Treatment recommendations for IVLBCL are largely based on retrospective studies and case reports. The combination of rituximab and cyclophosphamide, doxorubicin, VCR, and prednisone (R-CHOP) is widely used as first-line therapy, but with a PFS at 2 years of only 50-60% 6 outcome is inferior to non-intravascular diffuse large B-cell lymphoma.
To improve outcome, more intensive treatment approaches have been pursued in individual patients. Autologous hematopoietic stem cell transplantation (autoHSCT) has been reported to result in a more favorable outcome in single cases [7] [8] [9] [10] [11] [12] [13] [14] and small case series, almost exclusively in patients of Asian origin (Supplementary Material). In detail, in the pre-rituximab era, two out of four 5 and five out of seven 4 autografted patients with IVLBCL were described to survive without relapse. After introduction of rituximab, seven out of seven 6 and six out of six 15 patients have been reported to remain alive and relapse-free after autoHSCT.
The objective of the present study was to analyze for the first time the efficacy of autoHSCT for IVLBCL in a larger cohort of Western patients in the rituximab era.
This was a registry-based retrospective multicenter study including patients aged 18 years or over with histologically verified IVLBCL who underwent autoHSCT between 1 January 2002 and 31 December 2013, and were registered with the European Society for Blood and Marrow Transplantation database. Patient's informed consent was obtained locally at the time of autoHSCT. Baseline information and transplant data of eligible patients were downloaded from the European Society for Blood and Marrow Transplantation database. Centers were contacted to provide updated follow-up information as well as to submit the original written diagnostic report.
The primary end points studied were overall survival (time from autoHSCT to death from any cause) and PFS (time from autoHSCT to relapse/progressive disease or death from any cause, whatever Abbreviations: autoHSCT = autologous hematopoietic stem cell transplantation; autoSCT = autologous stem cell transplantation; BEAM = carmustine, etoposide, cytarabine and melphalan; BM = bone marrow; CHOP = cyclophosphamide, doxorubicin, VCR, and prednisone; CHP = cyclophosphamide, doxorubicin and prednisone; CNS = central nervous system; DHAP = dexamethasone, high-dose cytarabine, and cisplatin; f = female; HCVAD = cyclophosphamide, VCR, doxorubicin, dexamethasone, methotrexate and cytarabine; LACE = lomustine, cytarabine, cyclophosphamide and etoposide; LDH = lactate dehydrogenase; LN = lymph node; m = male; MTX = methotrexate; NA = not applicable; R = rituximab; TBC = thiotepa, busulfan and cyclophosphamide.
comes first). Secondary end points were incidence of relapse or progression, and non-relapse mortality (death from any cause other than relapse or progression). Survival curves for overall survival and PFS were calculated by the Kaplan-Meier method. A complete data set including follow-up data and the written diagnostic report could be retrieved for 19 patients from the European Society for Blood and Marrow Transplantation database who met the eligibility criteria. After exclusion of eight patients with a diagnostic report not confirmatory of the diagnosis of IVLBCL, the final cohort for analysis consisted of 11 patients ( Table 1 ). The median age at diagnosis of the 11 patients was 55 years (range 34-65). All had stage IV disease with central nervous system involvement in five patients, lung involvement in four patients, as well as bone marrow and spleen involvement in three patients each. Although complete data to assess the International Prognostic Index were not available, advanced stage along with elevated LDH in almost all patients suggests an overall unfavorable risk profile as per International Prognostic Index for this patient population. First-line treatment mainly was based on R-CHOP (10 of 11 patients). Seven patients received autoHSCT as part of the first-line treatment, three as part of salvage treatment, and in one patient, this information was not available. Disease status at autoHSCT was CR in 8 patients (73%) and PR in 3 patients (27%). The median time from diagnosis to autoHSCT was 6 months (range 4-31). The regimen most commonly employed for highdose therapy was BEAM (carmustin, etoposide, cytarabine and melphalan).
After a median follow-up of surviving patients for 51 months (range 11-95), eight patients were alive and free of progression. One patient (transplanted in first remission) died treatmentrelated, whereas relapse occurred in two patients, 15 and 27 months post autoHSCT, respectively, both with more than one previous treatment line. Two-year PFS and overall survival were 81% and 91%, respectively (Figure 1) . This is the first case series on autoHSCT in Western patients with IVLBCL in the rituximab era. Although Western patients have been reported to differ from Asian patients with IVLBCL in terms of clinical patterns, 1, 3, 4 the outcome of our patient cohort with a 2-year PFS of 82% is in line with that of autoHSCT in Asian case series, 4, 6, 15 but compares well with the 2-year PFS of 56% after standard R-CHOP. 6 Of note, none of the patients autografted in first remission had disease recurrence in our series despite central nervous system involvement in four of them.
The main limitation of our study obviously lies in its retrospective nature and the small sample size. However, owing to the rarity of IVLBCL, a prospective randomized trial on a larger number of patients will hardly be feasible. Moreover, an aggressive treatment approach including autoHSCT may not be tolerable by elderly unfit patients, whereas the median age of IVLBCL patients is beyond the sixth decade. 4, 5 Nevertheless, autoHSCT is manageable in patients up to an age of 65-70 years and thus in roughly half of all IVLBCL patients.
In conclusion, these data suggest that early autoHSCT may improve the results of standard induction chemoimmunotherapy in this rare high-risk diffuse large B-cell lymphoma subtype in patients up to an age of 65-70 years. 
